In Brief: Warner-Lambert/BASF
Warner-Lambert/BASF: Will jointly research, develop and market a new class of drugs that inhibit the interleukin-1 beta converting enzyme under a March 16 agreement. ICE generates the active form of the cytokine interleukin-1 beta, which is a mediator in early stages of inflammation and is thought to be involved in other neurodegenerative diseases, W-L says. Disease targets include rheumatoid arthritis, septic shock and Alzheimer's. BASF scientists have mapped the three-dimensional structure of ICE, and Parke-Davis scientists have cloned the ICE gene from rats. The two companies are equal owners of any resulting products or technologies, which would be marketed worldwide by BASF's Knoll AG and Parke-Davis...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth